Regulus Therapeutics Inc.
Index- P/E- EPS (ttm)-0.29 Insider Own0.40% Shs Outstand145.97M Perf Week-13.97%
Market Cap326.40M Forward P/E- EPS next Y-0.20 Insider Trans24.30% Shs Float139.78M Perf Month-28.84%
Income-28.50M PEG- EPS next Q-0.05 Inst Own45.30% Short Float2.18% Perf Quarter-30.54%
Sales- P/S- EPS this Y27.90% Inst Trans86.95% Short Ratio14.38 Perf Half Y-36.58%
Book/sh0.34 P/B6.09 EPS next Y4.80% ROA-51.40% Target Price1.50 Perf Year-74.92%
Cash/sh0.34 P/C6.06 EPS next 5Y39.60% ROE-67.10% 52W Range1.58 - 8.72 Perf YTD-34.29%
Dividend- P/FCF- EPS past 5Y55.50% ROI- 52W High-76.27% Beta2.07
Dividend %- Quick Ratio12.30 Sales past 5Y- Gross Margin- 52W Low31.35% ATR0.31
Employees25 Current Ratio12.30 Sales Q/Q- Oper. Margin- RSI (14)39.95 Volatility12.34% 11.60%
OptionableYes Debt/Eq0.09 EPS Q/Q45.40% Profit Margin- Rel Volume0.18 Prev Close2.07
ShortableYes LT Debt/Eq0.07 EarningsMay 12 AMC Payout- Avg Volume212.09K Price2.07
Recom2.30 SMA20-17.48% SMA50-11.41% SMA200-39.40% Volume39,226 Change0.00%
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $1
Jan-05-18Initiated Leerink Partners Outperform $2
Jun-13-17Reiterated Chardan Capital Markets Buy $5 → $2.50
Mar-06-17Reiterated Wedbush Outperform $8 → $6
Jan-30-17Downgrade Wells Fargo Outperform → Market Perform
Jan-30-17Downgrade Needham Buy → Hold
Dec-07-16Reiterated Chardan Capital Markets Buy $12 → $5
Nov-02-16Reiterated Needham Buy $10 → $9
Jul-25-16Reiterated Chardan Capital Markets Buy $14.50 → $12
Jun-28-16Reiterated Needham Buy $25 → $10
Jun-28-16Reiterated FBR Capital Outperform $30 → $9
Jun-28-16Reiterated Chardan Capital Markets Buy $20 → $13.50
Jun-07-16Reiterated Chardan Capital Markets Buy $15 → $20
Apr-13-16Initiated Chardan Capital Markets Buy $15
Dec-04-15Initiated Wells Fargo Outperform
Jun-09-15Initiated Guggenheim Buy
Apr-21-15Resumed FBR Capital Outperform $30
Nov-24-14Initiated Deutsche Bank Buy $30
Aug-07-14Reiterated FBR Capital Outperform $14 → $15
Aug-14-13Reiterated Needham Buy $8 → $12
Jun-21-22 08:00AM  
Jun-13-22 08:00AM  
Jun-02-22 08:00AM  
May-17-22 04:30PM  
May-12-22 04:05PM  
May-11-22 08:00AM  
May-05-22 04:05PM  
Mar-24-22 12:03PM  
Mar-10-22 04:05PM  
Mar-03-22 05:15PM  
Feb-24-22 08:00AM  
Feb-10-22 04:30PM  
Jan-26-22 10:00AM  
Jan-20-22 05:18PM  
Jan-19-22 09:38AM  
Jan-04-22 08:00AM  
Dec-03-21 08:30AM  
Dec-01-21 08:30AM  
Nov-30-21 05:23PM  
Nov-24-21 04:05PM  
Nov-10-21 05:45PM  
Nov-03-21 05:15PM  
Oct-28-21 03:05PM  
Oct-13-21 03:11PM  
Oct-12-21 04:05PM  
Sep-30-21 04:45PM  
Sep-09-21 04:40PM  
Sep-06-21 02:33PM  
Aug-10-21 05:55PM  
Aug-03-21 05:15PM  
Jun-30-21 09:33AM  
Jun-25-21 01:38PM  
Jun-21-21 07:00AM  
Jun-11-21 08:56AM  
May-21-21 10:47AM  
May-14-21 04:07PM  
May-13-21 05:35PM  
May-06-21 03:01PM  
May-03-21 09:25AM  
Apr-15-21 08:07AM  
Apr-07-21 08:07AM  
Mar-10-21 04:03AM  
Mar-09-21 04:07PM  
Mar-05-21 04:07PM  
Mar-04-21 12:30PM  
Feb-10-21 08:07AM  
Jan-27-21 08:07AM  
Jan-05-21 08:07AM  
Dec-09-20 08:54AM  
Dec-08-20 08:07AM  
Dec-02-20 07:00AM  
Dec-01-20 08:35AM  
Nov-29-20 02:33PM  
Nov-05-20 05:25PM  
Nov-03-20 12:31PM  
Nov-02-20 08:07AM  
Oct-15-20 08:07AM  
Oct-13-20 08:07AM  
Sep-11-20 08:07AM  
Sep-08-20 08:28AM  
Sep-03-20 08:07AM  
Aug-31-20 08:07AM  
Aug-13-20 06:05PM  
Aug-06-20 12:30PM  
Aug-03-20 08:07AM  
Jul-29-20 08:07AM  
Jul-22-20 08:07AM  
Jun-12-20 08:01AM  
May-14-20 04:07PM  
May-07-20 12:30PM  
Mar-12-20 04:37PM  
Mar-09-20 12:30PM  
Feb-13-20 04:30PM  
Jan-21-20 07:47AM  
Dec-22-19 07:44PM  
Dec-16-19 08:00AM  
Nov-18-19 08:07AM  
Nov-15-19 01:37PM  
Nov-12-19 05:55PM  
Nov-07-19 10:30AM  
Oct-16-19 04:15PM  
Sep-20-19 01:30PM  
Sep-12-19 08:00AM  
Sep-03-19 04:10PM  
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Drygin DenisChief Scientific OfficerFeb 04Buy0.2323,3145,36223,314Feb 07 05:09 PM
Hagan Joseph PPresident and CEOJan 26Buy0.22100,00021,520417,006Jan 26 04:13 PM